X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.70.

A number of research firms have issued reports on XFOR. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 target price for the company. Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Weiss Ratings cut X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th.

X4 Pharmaceuticals Trading Down 3.5%

NASDAQ:XFOR opened at $3.85 on Friday. The company has a market cap of $363.13 million, a PE ratio of -0.85 and a beta of 0.35. The business’s 50 day moving average is $3.99 and its two-hundred day moving average is $3.93. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The company had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. On average, analysts predict that X4 Pharmaceuticals will post -0.77 EPS for the current year.

Insider Activity

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer directly owned 167,750 shares of the company’s stock, valued at approximately $714,615. This trade represents a 4.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Pettinga Financial Advisors LLC purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth about $47,000. Perceptive Advisors LLC lifted its stake in X4 Pharmaceuticals by 6.7% during the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after buying an additional 423,196 shares in the last quarter. Bank of America Corp DE lifted its stake in X4 Pharmaceuticals by 321.3% during the first quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock valued at $622,000 after buying an additional 114,915 shares in the last quarter. SummitTX Capital L.P. acquired a new position in shares of X4 Pharmaceuticals in the first quarter worth about $46,000. Finally, Virtu Financial LLC acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter worth about $90,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.